Globe Life/$GL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Globe Life
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
- Ticker
- $GL
- Sector
- Finance
- Primary listing
- NYSE
- Employees
- 3,695
- Headquarters
- McKinney, United States
- Website
- home.globelifeinsurance.com
Globe Life Metrics
BasicAdvanced
$12B
10.66
$14.92
0.44
$1.26
0.83%
Price and volume
Market cap
$12B
Beta
0.44
52-week high
$191.55
52-week low
$127.85
Average daily volume
570K
Dividend rate
$1.26
Financial strength
Total debt to equity
0.557
Interest coverage (TTM)
11.32%
Profitability
EBITDA (TTM)
1,652.123
Gross margin (TTM)
33.10%
Net profit margin (TTM)
18.89%
Operating margin (TTM)
25.82%
Effective tax rate (TTM)
18.79%
Revenue per employee (TTM)
$1,700,000
Management effectiveness
Valuation
Price to earnings (TTM)
10.659
Price to revenue (TTM)
1.977
Price to book
1.99
Price to tangible book (TTM)
2.16
Dividend yield (TTM)
0.79%
Forward dividend yield
0.83%
Growth
Revenue change (TTM)
5.62%
Earnings per share change (TTM)
8.35%
3-year revenue growth (CAGR)
5.35%
10-year revenue growth (CAGR)
4.89%
3-year earnings per share growth (CAGR)
15.60%
10-year earnings per share growth (CAGR)
12.90%
3-year dividend per share growth (CAGR)
-32.62%
10-year dividend per share growth (CAGR)
-6.87%
What the Analysts think about Globe Life
Analyst ratings (Buy, Hold, Sell) for Globe Life stock.
Analyst projections of the future price of Globe Life stock.
Bulls say / Bears say
Third-quarter premiums rose 7%, led by 16% growth in health, and management expects total premium growth of 6%–8% in 2027. That points to continued expansion in its core insurance business. (Globe Life)
Globe Life plans $725 million–$775 million of share repurchases in 2026 and forecasts $850 million–$950 million of parent-company excess cash flow in 2027. If delivered, that gives it capacity for substantial shareholder returns. (Globe Life)
The portfolio’s long-term investment yield rose to 5.52% from 5.46% a year earlier, while new fixed-maturity investments earned 6.4%. Higher reinvestment yields could support future investment income. (The Motley Fool)
Globe Life cut its 2026 operating-earnings guidance to $15.35–$15.65 per share, below the range it gave in July. The reduction weakens near-term earnings momentum. (Globe Life, Globe Life)
United American’s health underwriting result swung to a $6 million loss from a $16 million profit a year earlier, including about $16 million of Evry losses and $7 million of excess Medicare Supplement claims. Persistent high-severity claims or delayed pricing responses could pressure margins further. (Globe Life)
Globe Life’s latest quarterly filing describes unresolved securities and derivative litigation involving allegations about disclosures and oversight. The cases create legal and reputational uncertainty, and their eventual costs are not yet clear. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
Globe Life Financial Performance
Revenues and expenses
Globe Life Earnings Performance
Company profitability
Upcoming events
No upcoming events
Globe Life News
AllArticlesVideos
Funds containing Globe Life
AllUSDEURGBP
Fund name | Fund size | $GL weighting |
|---|---|---|
Invesco S&P 500 Low Volatility£SPLG | $143M | 0.91% |
SPDR S&P 500 Low Volatility$LOWV | $113M | 0.91% |
SPDR S&P 500 Low Volatility£USLV | $113M | 0.91% |
iShares Ageing Population$AGED | $953M | 0.49% |
iShares Ageing Population£AGES | $953M | 0.49% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.